Table 1 Demographic and clinical data from the final sample employed for data analyses (2 eCH participants excluded for algorithm failure). The number of patients with ongoing prophylactic treatment also comprises the number of patients with ongoing lithium treatment

Statistics and p-values

cCH

eCH

CTRL

cCH vs eCH

cCH vs CTRL

eCH vs CTRL

Participants

57

48

59

n.a

n.a

n.a

Age (ys; M ± SD)

45 ± 11

46 ± 11

44 ± 10

U = 1243

0.42

U = 1653;

p = 0.88

U = 1268

p = 0.355

Females/Males

11/46

5/43

12/47

X² (1,105) = 1.59

0.21

X² (1,116) = 0.02

p = 0.89

X² (1,107) = 1.95

p = 0.163

Left, right, shifting CH attacks

20, 29, 8

22, 22, 4

n.a

X² (1,105) = 0.02

0.88

n.a

n.a

Daily attacks

3 ± 2

2.5 ± 1.6

n.a

U = 1291

0.19

n.a

n.a

Years of chronic disease (M ± SD)

8 ± 6.8

n.a

n.a

n.a

n.a

n.a

n.a

Pts under Lithium

15

4

n.a

X² (1,105) = 5.68

0.017*

n.a

n.a

Pts under prophylactic treatment

45

17

n.a

X² (1,105) = 20.42

< 0.001*

n.a

n.a

VAS before MRI (Median- range)

0 (0–3)

0 (0)

n.a

U = NaN (var. = 0)

n.a

n.a

n.a

cCH (DS1)

cCH (DS2)

Statistics and p-values

eCH ‘in’

eCH ‘out’

Statistics and p-values

Participants

28

29

n.a

23

25

Age (ys; M ± SD)

45 ± 11

45 ± 10

U = 397

0.89

51 ± 8

42 ± 11

U = 414

0.009*

Females/Males

5/23

6/23

X² (1,57) = 0.073

0.79

1/22

4/21

X² (1, 48) = 1.74

0.19

Left, right, shifting CH attacks

12, 15, 1

8, 14, 7

X² (1,57) = 0.16

0.7

9, 13, 1

13, 9, 3

X² (1, 48) = 2.32

0.15

Daily attacks (M ± SD)

4 ± 2.1

2 ± 1.3

U = 627

< 0.001*

2.5 ± 1.9

2.4 ± 1.2 (**)

U = 181

0.62

Years of chronic disease (M ± SD)

7 ± 6.2

9 ± 7.4

U = 349

0.37

n.a

n.a

n.a

Pts under Lithium

11

4

X² (1, 57) = 4.77

0.029*

4

0

X² (1, 48) = 4.74

0.029*

Pts under prophylactic treatment

24

21

X² (1, 57) = 1.52

0.22

16

1

X² (1, 48) = 22.5

< 0.001*